Filing Details
- Accession Number:
- 0001649094-24-000069
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-09-18 16:24:45
- Reporting Period:
- 2024-09-17
- Accepted Time:
- 2024-09-18 16:24:45
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1649094 | Vaxcyte Inc. | PCVX | Biological Products, (No Disgnostic Substances) (2836) | 464233385 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1829111 | Teri Loxam | C/O Vaxcyte, Inc. 825 Industrial Road, Ste. 300 San Carlos CA 94070 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-09-17 | 6,250 | $22.70 | 13,425 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-09-17 | 241 | $114.64 | 13,184 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-09-17 | 1,445 | $115.32 | 11,739 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-09-17 | 4,308 | $116.62 | 7,431 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-09-17 | 256 | $117.51 | 7,175 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Disposition | 2024-09-17 | 6,250 | $0.00 | 6,250 | $22.70 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 12,500 | 2032-05-31 | No | 4 | M | Direct |
Footnotes
- The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 18, 2024.
- The price reported is a weighted-average price. The shares were sold at prices ranging from $113.93 to $114.74. The reporting person will provide upon request to the SEC, the issuer or security holder of theissuer, full information regarding the number of shares sold at each separate price.
- The price reported is a weighted-average price. The shares were sold at prices ranging from $115.04 to $115.64. The reporting person will provide upon request to the SEC, the issuer or security holder of theissuer, full information regarding the number of shares sold at each separate price.
- The price reported is a weighted-average price. The shares were sold at prices ranging from $116.25 to $117.04. The reporting person will provide upon request to the SEC, the issuer or security holder of theissuer, full information regarding the number of shares sold at each separate price.
- Option is fully vested and exercisable.
Billionaire Hedge Funds
